Clinical Trial Update: TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on combining transarterial chemoembolization (TACE) with anlotinib for middle-advanced hepatocellular carcinoma (HCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: UNKNOWN